Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to eva… Read more
Lin BioScience Inc. (6696) - Total Assets
Latest total assets as of June 2025: NT$5.49 Billion TWD
Based on the latest financial reports, Lin BioScience Inc. (6696) holds total assets worth NT$5.49 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lin BioScience Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Lin BioScience Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lin BioScience Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Lin BioScience Inc.'s total assets of NT$5.49 Billion consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 26.9% |
| Accounts Receivable | NT$18.92 Million | 0.3% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$118.40 Million | 2.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Lin BioScience Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lin BioScience Inc.'s current assets represent 96.8% of total assets in 2024, an increase from 52.1% in 2019.
- Cash Position: Cash and equivalents constituted 26.9% of total assets in 2024, down from 47.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 2.1% of total assets.
Lin BioScience Inc. Competitors by Total Assets
Key competitors of Lin BioScience Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lin BioScience Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lin BioScience Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lin BioScience Inc. is currently not profitable relative to its asset base.
Lin BioScience Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 41.18 | 32.95 | 20.94 |
| Quick Ratio | 41.18 | 32.95 | 20.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$5.21 Billion | NT$ 4.20 Billion | NT$ 1.59 Billion |
Lin BioScience Inc. - Advanced Valuation Insights
This section examines the relationship between Lin BioScience Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.54 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 53.7% |
| Total Assets | NT$5.53 Billion |
| Market Capitalization | $751.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lin BioScience Inc.'s assets below their book value (0.14 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lin BioScience Inc.'s assets grew by 53.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lin BioScience Inc. (2019–2024)
The table below shows the annual total assets of Lin BioScience Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.53 Billion | +53.67% |
| 2023-12-31 | NT$3.60 Billion | +94.20% |
| 2022-12-31 | NT$1.85 Billion | +100.61% |
| 2021-12-31 | NT$923.23 Million | -24.25% |
| 2020-12-31 | NT$1.22 Billion | +390.05% |
| 2019-12-31 | NT$248.72 Million | -- |